PE20241731A1 - Procesos para la preparacion de degradadores selectivos del receptor de estrogeno - Google Patents
Procesos para la preparacion de degradadores selectivos del receptor de estrogenoInfo
- Publication number
- PE20241731A1 PE20241731A1 PE2024001567A PE2024001567A PE20241731A1 PE 20241731 A1 PE20241731 A1 PE 20241731A1 PE 2024001567 A PE2024001567 A PE 2024001567A PE 2024001567 A PE2024001567 A PE 2024001567A PE 20241731 A1 PE20241731 A1 PE 20241731A1
- Authority
- PE
- Peru
- Prior art keywords
- processes
- estrogen receptor
- selective estrogen
- degradators
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305520P | 2022-02-01 | 2022-02-01 | |
| US202263409060P | 2022-09-22 | 2022-09-22 | |
| PCT/US2023/011671 WO2023150056A1 (en) | 2022-02-01 | 2023-01-27 | Processes for the preparation of selective estrogen receptor degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241731A1 true PE20241731A1 (es) | 2024-08-19 |
Family
ID=85382684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001567A PE20241731A1 (es) | 2022-02-01 | 2023-01-27 | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11926634B2 (https=) |
| EP (1) | EP4472982A1 (https=) |
| JP (3) | JP7387926B2 (https=) |
| KR (2) | KR20250006312A (https=) |
| AU (2) | AU2023216654B2 (https=) |
| CA (1) | CA3243621A1 (https=) |
| CO (1) | CO2024009411A2 (https=) |
| CR (1) | CR20240283A (https=) |
| DO (1) | DOP2024000150A (https=) |
| IL (1) | IL313886A (https=) |
| JO (1) | JOP20240169A1 (https=) |
| MX (1) | MX2024009453A (https=) |
| PE (1) | PE20241731A1 (https=) |
| TW (2) | TW202523669A (https=) |
| WO (1) | WO2023150056A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020137965A (ja) * | 2019-03-01 | 2020-09-03 | 株式会社三洋物産 | 遊技機 |
| US20240199629A1 (en) * | 2022-02-01 | 2024-06-20 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100849559B1 (ko) | 2004-01-22 | 2008-07-31 | 일라이 릴리 앤드 캄파니 | 혈관운동 증상의 치료를 위한 선택적 에스트로겐 수용체조절제 |
| US20080221163A1 (en) | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
| EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
| AU2012257802A1 (en) | 2011-05-17 | 2013-10-31 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's tyrosine kinase |
| CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| WO2016097071A1 (en) | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| CN112424205B (zh) | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
| TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| KR20220046586A (ko) | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
| CA3169679A1 (en) | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| WO2021191378A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| TWI837605B (zh) | 2021-03-09 | 2024-04-01 | 美商美國禮來大藥廠 | 使用serd組合給藥方案治療癌症之方法 |
| TWI894443B (zh) | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2023
- 2023-01-27 CA CA3243621A patent/CA3243621A1/en active Pending
- 2023-01-27 CR CR20240283A patent/CR20240283A/es unknown
- 2023-01-27 KR KR1020247041076A patent/KR20250006312A/ko active Pending
- 2023-01-27 WO PCT/US2023/011671 patent/WO2023150056A1/en not_active Ceased
- 2023-01-27 PE PE2024001567A patent/PE20241731A1/es unknown
- 2023-01-27 IL IL313886A patent/IL313886A/en unknown
- 2023-01-27 AU AU2023216654A patent/AU2023216654B2/en active Active
- 2023-01-27 EP EP23707540.3A patent/EP4472982A1/en active Pending
- 2023-01-27 KR KR1020247028876A patent/KR102743629B1/ko active Active
- 2023-01-27 US US18/160,457 patent/US11926634B2/en active Active
- 2023-01-27 MX MX2024009453A patent/MX2024009453A/es unknown
- 2023-02-01 JP JP2023013779A patent/JP7387926B2/ja active Active
- 2023-02-01 TW TW113140271A patent/TW202523669A/zh unknown
- 2023-02-01 TW TW112103450A patent/TWI863110B/zh active
- 2023-08-28 JP JP2023138310A patent/JP7805336B2/ja active Active
-
2024
- 2024-07-16 CO CONC2024/0009411A patent/CO2024009411A2/es unknown
- 2024-07-30 JO JOJO/P/2024/0169A patent/JOP20240169A1/ar unknown
- 2024-07-31 DO DO2024000150A patent/DOP2024000150A/es unknown
-
2025
- 2025-09-04 JP JP2025146941A patent/JP2025183283A/ja active Pending
- 2025-09-16 AU AU2025234145A patent/AU2025234145A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024009411A2 (es) | 2024-07-29 |
| KR20240135862A (ko) | 2024-09-12 |
| US20230242545A1 (en) | 2023-08-03 |
| MX2024009453A (es) | 2024-08-09 |
| JP2025183283A (ja) | 2025-12-16 |
| AU2023216654A1 (en) | 2024-07-11 |
| CR20240283A (es) | 2024-09-03 |
| AU2025234145A1 (en) | 2025-10-02 |
| US11926634B2 (en) | 2024-03-12 |
| DOP2024000150A (es) | 2024-08-30 |
| IL313886A (en) | 2024-08-01 |
| WO2023150056A1 (en) | 2023-08-10 |
| TW202346300A (zh) | 2023-12-01 |
| JP7387926B2 (ja) | 2023-11-28 |
| KR102743629B1 (ko) | 2024-12-17 |
| AU2023216654B2 (en) | 2025-09-25 |
| CA3243621A1 (en) | 2023-08-10 |
| KR20250006312A (ko) | 2025-01-10 |
| JP2023112696A (ja) | 2023-08-14 |
| TWI863110B (zh) | 2024-11-21 |
| JOP20240169A1 (ar) | 2024-07-30 |
| JP7805336B2 (ja) | 2026-01-23 |
| TW202523669A (zh) | 2025-06-16 |
| JP2023162334A (ja) | 2023-11-08 |
| EP4472982A1 (en) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241731A1 (es) | Procesos para la preparacion de degradadores selectivos del receptor de estrogeno | |
| PE20241341A1 (es) | Compuestos terapeuticos para la infeccion por el virus vih | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| PE20220705A1 (es) | Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin y compuestos relacionados como inhibidores de proteina bcl-xl y agentes proapoptoticos para el tratamiento del cancer | |
| PE20241063A1 (es) | Composiciones y metodos para la inhibicion de ras | |
| CL2021000045A1 (es) | Degradadores selectivos del receptor de estrógeno | |
| RU2008130111A (ru) | (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний | |
| JP2006501181A5 (https=) | ||
| JP2009521494A5 (https=) | ||
| AR119479A1 (es) | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer | |
| AR081393A2 (es) | Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento | |
| BRPI0418245B8 (pt) | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes | |
| AR072611A1 (es) | Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne. | |
| PE20241188A1 (es) | Agonistas de rxfp1 | |
| BR112023001048A2 (pt) | Agonista de ppar-delta cristalino | |
| PE20241352A1 (es) | Inhibidores heteroaromaticos biciclicos de la klk5 | |
| CL2023000387A1 (es) | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos | |
| AR126961A1 (es) | Sintesis de nirogacestat | |
| UY28688A1 (es) | Derivados de amida | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| BR112022017779A2 (pt) | Imunomodulação de azaletos de o-het-arila | |
| PE20010149A1 (es) | Derivados del indol como agentes melatoninergicos | |
| PE20241726A1 (es) | Compuestos n-acilhidrazonicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtencion, composiciones, usos, metodos de tratamiento de estos y kits | |
| BRPI0614122A8 (pt) | composto derivado de quinolina, composição farmacêutica e uso do referido composto |